Congress Trades

Jeffrey M LeidenFiled

Executive ChairmanExecutiveDirectorCIK 1242825
Net · 12 months
-$60.9M
Open-market buys − sales
Sold · 12 months
$60.9M
$0 in 90d · 24 sales on record
Bought · 12 months
$0
$0 in 90d · 0 buys on record
Under 10b5-1
100%
Share of sale value under a trading plan
Last trade
Feb 24, 2026
Filed Feb 26, 2026 · 48 rows

Monthly open-market value · 24 months Filed

  • Bought (open market)
  • Sold (open market)

Unusual activity Estimated

Whale score 95Whale watch
  • 27Exec saleDec 3, 2025

    VRTX Chair Jeffrey M Leiden sold $7.1M (10b5-1 plan)

    Details
    Insider
    Jeffrey M Leiden
    Company
    VERTEX PHARMACEUTICALS INC / MA
    Ticker
    VRTX
    Tx kind
    open_market_sale
    Tx date
    Dec 3, 2025
    Shares
    15,681
    Price
    $452
    Value
    $7.1M
    Is 10b5 1
    Yes
  • 32Exec saleNov 14, 2025

    VRTX Chair Jeffrey M Leiden sold $14.2M (10b5-1 plan)

    Details
    Insider
    Jeffrey M Leiden
    Company
    VERTEX PHARMACEUTICALS INC / MA
    Ticker
    VRTX
    Tx kind
    open_market_sale
    Tx date
    Nov 14, 2025
    Shares
    32,234
    Price
    $440
    Value
    $14.2M
    Is 10b5 1
    Yes
  • 29Exec saleNov 14, 2025

    VRTX Chair Jeffrey M Leiden sold $9.4M (10b5-1 plan)

    Details
    Insider
    Jeffrey M Leiden
    Company
    VERTEX PHARMACEUTICALS INC / MA
    Ticker
    VRTX
    Tx kind
    open_market_sale
    Tx date
    Nov 14, 2025
    Shares
    21,330
    Price
    $441
    Value
    $9.4M
    Is 10b5 1
    Yes
  • 28Exec saleNov 13, 2025

    VRTX Chair Jeffrey M Leiden sold $8.2M (10b5-1 plan)

    Details
    Insider
    Jeffrey M Leiden
    Company
    VERTEX PHARMACEUTICALS INC / MA
    Ticker
    VRTX
    Tx kind
    open_market_sale
    Tx date
    Nov 13, 2025
    Shares
    18,528
    Price
    $440
    Value
    $8.2M
    Is 10b5 1
    Yes

Transactions

Independent third-party platform; not affiliated with or endorsed by any member of Congress. Data sourced from publicly available filings and records. Portfolio, holdings, returns, and allocations are estimates and may differ from actual values. Informational and educational only; not investment advice. Shares, prices and post-transaction holdings are exactly as reported on SEC Form 4; the whale score is a model ranking of that filed activity.